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Abstract
Objectives The aim of this review is to examine the
causes, pathophysiology and experimental models of non-
infectious pharyngitis (sore throat).
Introduction The causes of sore throat can be infectious
(viruses, bacteria, and fungi) or non-infectious, although
the relative proportion of each is not well documented.
Methods A PubMed database search was performed for
studies of non-infectious sore throat.
Results and conclusions Non-infectious causes of sore
throat include: physico-chemical factors, such as smoking,
snoring, shouting, tracheal intubation, medications, or con-
comitant illness; and environmental factors including indoor
and outdoor air pollutants, temperature and humidity, and
hazardous or occupational irritants. The pathophysiology
underlying non-infectious sore throat is largely uncharac-
terised, although neurogenic inflammation looks to be a
promising candidate. It is likely that there will be individual
disposition factors or the coincidence of more than one
irritant with possible—up to now unknown—interactions
between them. Therefore, experimental models with defined
conditions and objective endpoints are needed. A new model
using cold dry air to directly induce pharyngeal irritation in
humans, with pharyngeal lavage to measure biomarkers,
may provide a useful tool for the study of mechanisms and
treatment of non-infectious sore throat.
Keywords Air pollution  Cold dry air 
Experimental model  Inflammation 
Occupational exposure  Therapy  Pain
Introduction
Pharyngitis is inflammation of the oropharynx. It is com-
monly referred to as sore throat, although this term is often
used imprecisely and is poorly defined. Hence, whilst sore
throat may be the symptom described by the patient,
examination might also reveal nasopharyngitis (that is,
including the nasopharyngeal mucosa). The exact site of
the irritation/inflammation is often not identified, with
some studies relying on a patient-reported diagnosis (that
is, ‘sore throat’). These factors potentially complicate the
study (and treatment) of sore throat. The following review
will focus on sore throat as the primary symptom, which
implies reported irritation and pain caused by inflammation
and/or irritation of the oro (medium part) and hypopharynx
(lower part of the pharynx). As mentioned, there exist also
overlapping symptoms to nasopharyngitis (upper part of
the pharynx) but rhinitis or rhinosinusitis are usually
diagnosed in those patients and sore throat is not the pri-
mary symptom.
Sore throat may have an infectious or non-infectious
aetiology, although these sometimes overlap. Most cases
are infectious, with a large proportion (up to 40 %) caused
by rhinovirus and adenovirus. Other viruses including
coronavirus, influenza, parainfluenza, Epstein Barr, and
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herpes simplex have also been implicated [1]. Of the
bacterial sore throats, group A b-haemolytic streptococcus
is most frequently (5–36 %) isolated [1, 2]. Other organ-
isms to which sore throat has been attributed include
Mycoplasma pneumonia and Arcanobacterium haemolyti-
cus [1]. Rarely, candidal infections and other fungi and
parasites have also been observed [1].
A proportion of sore throats have non-infectious aetiol-
ogies, although the relative prevalence versus infectious
cases is not well documented. This is probably because it is
a costly and difficult area to study. The non-infectious
causes of sore throat are extremely varied, and include
physico-chemical factors (for example smoking, snoring,
shouting, drugs) and environmental factors (for example
pollution, temperature, humidity/air conditioning). An
approximation might be obtained by identifying people
with sore throat in the absence of any other symptom (e.g.
rhinosinusitis) or with persistent sore throat (Fig. 1); but
this does not definitively exclude a viral, bacterial, or fungal
cause. In fact, quantifying the prevalence of non-infectious
sore throat would likely require the active identification and
exclusion of all potential infectious causes.
Overall, sore throat is a very common complaint and a
frequent reason for seeking medical care [3]. Of 15,788
respondents (aged 14 years or older) in a Scottish postal
survey, 31 % reported they had experienced severe sore
throat or tonsillitis in the previous year [4]. In the USA, acute
pharyngitis accounts for 1–2 % of all visits to outpatient
departments, physician offices, and emergency departments
[5]. Many people do not seek medical care when they have a
sore throat [6], although geographical variation is consider-
able, dependent on social factors, access to and cost of
healthcare, and attitudes to antibiotic prescribing.
When patients with sore throat do present to primary
care, the optimal management is controversial. This is
because, relatively rarely, sore throat can be serious [7].
Furthermore, whilst antibiotics may provide only modest
absolute benefits [8], there are few other prescription
options available for sore throat. Recurrent severe episodes
of sore throat might indicate tonsillectomy, while concur-
rent severe symptoms such as difficulty breathing or
swallowing usually require hospital admission [2]. The
main cause for concern though is the risk of rheumatic
fever and suppurative complications in patients with group
A b-haemolytic streptococcus and for this reason many
doctors, particularly in the USA, exercise caution [9].
Other potential complications include post-viral olfactory
dysfunction [10] and anosmia (which might be prevented
by vaccination in the future). A review of guidelines found
that recommended management strategies vary widely
[11]. In some countries sore throat is considered to be self-
limiting and swabbing and antibiotics are not routine,
whereas, others recommend microbiological investigation
with subsequent antibiotics for confirmed streptococcal
cases [11]. Non-steroidal anti-inflammatory drugs and
paracetamol are recommended for symptomatic relief [2,
12], while the relative risks and benefits of corticosteroids
require further study [2, 13]. The management of sore
throat is, therefore, far from standardised or evidence
based.
It is clear then that the majority of people with sore
throat have a benign self-limiting illness and many do not
present for medical care [6]. Amongst these are a largely
unquantified population with non-infectious aetiologies,
about which little is understood and for whom the optimal
treatment strategy is unclear. The objective of this review
was to collate the information on non-infectious sore
throat, particularly the proposed aetiologies and mecha-
nisms involved.
Causes of non-infectious sore throat
Physico-chemical factors
A wide variety of physico-chemical factors have been
implicated in causing sore throat, including cigarette
smoke inhalation, snoring, tracheal intubation, shouting,
and concomitant illness or drug effects.
Smoking is a risk factor for sore throat [14], in both
smokers themselves and in those exposed to secondary
smoke (passive smoking). Cigarette smoking was signifi-
cantly associated with sore throat/cough in US college
students [15], and frequency of cigarette smoking and sore
throat were correlated in Japanese women [16]. Passive
smoking was significantly associated with sore throat in 46
French non-smokers [17], 382 Australian non-smoking
indoor workers [18], and non-smoking Australian nightclub
and casino workers [19]. Furthermore, a questionnaire
Fig. 1 Schematic representation of typical course of sore throat of
infectious and non-infectious aetiology
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study reported a significant relationship between children’s
sore throats and maternal smoking [20].
Snoring is frequently associated with sore throat, and the
two have risk factors such as smoking [21] in common,
although the direction of causality is not always clear. A
high frequency of sore throat is a risk factor for habitual
snoring in children [22] and sore throat was reported by
over half of those snoring children who were subsequently
diagnosed with obstructive sleep apnoea [23]. Sore throat
may also be associated with obstructive sleep apnoea in
adults [24]. Sleep apnoea is a key factor for the manifes-
tation of secondary hypertension.
Tracheal intubation and laryngeal mask airways are
common causes of sore throat in people undergoing general
anaesthesia [24–27]. The reported incidence of postopera-
tive sore throat varies widely, but is generally higher for
tracheal intubation than for laryngeal mask airway [28].
For patients undergoing tracheal intubation, an incidence of
around 28–45.5 % [27, 29]— and as high as 70 % [30]—
has been reported. For laryngeal mask airway, the inci-
dence is lower—in the region of 3.5–21.4 % [27, 29, 31].
Shouting and voice loading may cause sore throat, as
reported by people in professions that require use (and
overuse) of their voice for their work. For example, aero-
bics instructors have reported an increased incidence of
sore throat unrelated to illness since beginning instructing
[32] and the frequency of aerobics classes has been shown
to significantly correlate with sore throat symptoms in
instructors [33]. Sore throat is also reported by school
teachers [34]. Furthermore, sore throat can occur as a
secondary consequence of functional dysphonia [35] as
well as vice versa.
Drug-induced sore throat is a notable adverse effect of
some medications, including angiotensin-converting
enzyme (ACE) inhibitors [36] and chemotherapy agents.
Sore throat is also a common problem in asthmatics taking
inhaled corticosteroids [37–39], although these data may be
in part confounded by a potential steroid-induced increased
susceptibility to infection, including mycoses. In fact,
people taking a wide variety of other drugs frequently
report sore throat as an adverse effect, but in many cases
the symptom will be coincidental (that is, probably infec-
tious sore throat and at a similar rate to placebo).
Concomitant illness can directly result in sore throat.
For example, Kawasaki disease (a mucocutaneous vascu-
litis) typically causes pharyngitis in both adults and
children [40]. Furthermore, chronic pharyngitis is a com-
mon manifestation of gastroesophageal reflux disorder
[41], with this presentation now termed laryngopharyngeal
reflux disorder [42]. While in these cases the sore throat
can be considered to be a direct manifestation of the
underlying condition, other illnesses may be associated
with sore throat due to a consequent increased
predisposition to infection. This may be the case for the
often cited link with thyroid disease, where 41 % of
patients with newly diagnosed thyroiditis report sore throat
as a first symptom [43].
Environmental factors
A wide variety of environmental factors have been cited as
causes of sore throat, including general air pollution, spe-
cific pollution related to occupation, hazard, or industry,
and pollution encountered in indoor environments. How-
ever, because the data are often epidemiological and
individual pollutants are rarely emitted in isolation, it is not
always possible to identify the precise cause of symptoms.
Patients with allergic rhinitis [44] as well as those with
postnasal drip [7], non-allergic rhinitis, and persistent cough
may also experience sore throat as a secondary symptom.
Ambient air pollution is a common cause of sore throat.
The factors implicated include ozone, nitrogen oxides, and
fine dust.
Urban living and traffic fumes are frequently associated
with sore throat. In children in Hong Kong, sore throat
decreased when fuel sulphur levels were reduced [45],
whilst exposure to vehicle emissions was linked with throat
pain and chronic pharyngitis in Shanghai bus drivers/con-
ductors/taxi drivers [46] and lack of air conditioning with
frequent sore throat in Hong Kong bus and tram drivers
[47]. Nitrogen dioxide has also been implicated [48, 49], as
well as photochemical oxidants such as ozone (O3) [50, 51].
Occupational or hazard-associated irritants that have
been reported to cause sore throat include particulates,
fumes, chemicals, and odours. Laryngitis has also been
reported [52].
Particulates and fumes from a wide variety of industries
have been implicated in sore throat, including pulp mills
[53], woodworking [54], cement works [55], brick kilns
[56], and factory exhaust emissions [57]. The burning of
gas creates multiple pollutants, including nitrogen oxides,
particulates, and volatile organic compounds, and gas-
related pollution has been linked with sore throat in several
studies [58, 59]. Cooking and fires are important sources of
pollutants worldwide [60], and in US non-smoking women,
each hour of fireplace use was associated with (little but
measurable) increased episodes of sore throat (relative risk
1.04; 95 % CI 1.00–1.08) [61].
A variety of chemicals have been reported to cause sore
throat including organic screen-printing solvents [62],
boron oxide, boron acid, and borax dust [63, 64], fluori-
nated hydrocarbons [65], machining coolants in the metal
working industry [66], nitrogen trichloride from indoor
swimming pools [67], chemical odours [68], and crude oil
spills [69–71]. In the newspaper printing industry—which
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uses multiple chemicals including organic solvents, filler
materials, and inks—a higher than expected incidence of
chronic pharyngitis has been reported [72]. Sore throat is
also a frequently-reported (72 %) symptom [73] in people
with multiple chemical sensitivity syndrome.
The US World Trade Center disaster (9/11) resulted in
uncharacterised hazardous exposures that are thought to be
the cause of the upper airway inflammation seen in many of
those exposed [74]. In 10,378 fire fighters, sore throat was
rare before the disaster (3.2 % reported frequent sore
throat), but was the most common respiratory symptom in
the year afterwards (62.4 %), declining and plateauing
thereafter (36 % in 2 years, and 37 % in 4 years) [75].
Along with cough, sore throat was considered to be the
most sensitive initial indicator of respiratory insult [75].
Volcano eruptions emit sulphur dioxide and other gasses
that may react with atmospheric components, and have
been reported to cause sore throat. For example, sore/dry
throat was significantly associated with volcanogenic sul-
phur dioxide and fine sulphate particles in Hawaii [76–78],
and the hourly incidence of sore throat showed clear
exposure–response relationships with post-eruptive SO2
concentrations [79].
Complaints of sore throat are frequent in communities
with confined animal facilities, wastewater treatment plants,
and biosolids recycling operations [80]. Sore throat was also
significantly more prevalent in Greek solid waste collectors
versus other workers [81]. Pig farming may be a particular
cause of sore throat in nearby residents [82], with a 10 EU/
mg increase in endotoxin being associated with increased
log odds (0.10 ± 0.05) of sore throat [83]. Farmers are
additionally exposed to pesticides, and this was attributed as
the cause of pharyngitis in a study of farmers versus other
workers in the United Arab Emirates [84].
These studies reveal that occupational and hazard-
associated irritants, including particulates, chemicals,
fumes and gasses, and endotoxin are well-documented
causes of sore throat.
Indoor air pollution causes sick building syndrome,
including sore throat. In the building assessment survey and
evaluation (BASE) study, 7.1 % of workers in 41 large office
buildings reported sore or dry throat [85]. The underlying
source of pollutants is thought to be poorly maintained
moisture-related heating, ventilating, and air-conditioning
components such as cooling coils and humidification sys-
tems [86]. Thus, symptom prevalence is higher in buildings
ventilated mechanically or with air-conditioning compared
with naturally ventilated buildings [87, 88]. The specific
pollutants responsible are not well characterised. Ozone
brought into the building through the ventilation system [89],
and its interaction with ventilation filters [90], has been
implicated, as have particulates [91]. Damp and mouldy
buildings also cause sore throats [92, 93].
Temperature and humidity affect mucus membranes,
and have been linked with sore throat symptoms. Heated
air causes nasal pain [94] and working regularly in a cold
environment causes rhinitis and sore throat as well as
changes in lung function [95]. Humidity is also important,
with the overall intensity of sick building syndrome
symptoms increasing when indoor air is not humidified
[96]. Experimentally, cold dry air induces nasal inflam-
mation [97, 98], and causes more nasal pain than
humidified dry air [94]. However, a population-based study
showed that both cold temperature and low humidity
appear to independently increase the risk of sore throat
[99].
Management of non-infectious sore throat
There has been little systematic assessment of treatments
for sore throat of non-infectious aetiology, and the field is
hampered by a lack of objective outcomes, with most
studies relying on subjective (self-reported) endpoints. By
definition, studies of antibiotic treatment for sore throat are
in infectious populations. Studies of non-antibiotic treat-
ment are generally similarly confounded by the inclusion
criteria ‘acute pharyngitis’ or ‘chronic pharyngitis’ which
will likely be of mixed aetiology. A population with sore
throat secondary to functional dysphonia might better
reflect the non-infectious aetiologies, but such studies are
few. Defined non-infectious study populations are, there-
fore, required. Many of the current data are unreliable for
determining the efficacy of treatments for non-infectious
sore throat, although some parallels can be drawn.
It is likely that the efficacy of non-antibiotic treatments
that has been reported in acute (mostly infectious) sore
throat might also be seen in non-infectious sore throat. This
extrapolation is based on the assumption that simple
analgesia and anti-inflammatory effects are likely to be
effective whatever the aetiology, especially if neurogenic
inflammation is involved (see below). A systematic review
in acute sore throat found that treatments effective on early
outcomes (\24 h) included steroids, non-steroidal anti-
inflammatory drugs (NSAIDs), caffeine, and paracetamol,
while paracetamol and NSAIDs also had a benefit on later
([24 h) outcomes [12]. These treatments might also work
for non-infectious sore throat.
There have been some studies in chronic pharyngitis,
but these are mostly small. Flurbiprofen has been shown to
be effective [100], as have Chinese herbs used in combi-
nation with acupuncture [101]; Chinese herbs have been
the subject of a systematic review [102]. Inhaled natural
ether oils have also been used [103], although the com-
position is mostly unknown. A Russian study of 22 patients
with aggravated chronic subatrophic pharyngitis against a
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background of acute respiratory viral infection showed that
amylmetacresol/dichlorobenzyl alcohol lozenges (Strep-
sils, Reckitt Benckiser Healthcare Ltd) resulted in a
marked and durable reduction in pain symptoms, which
was reported immediately after the first dose, and resulted
in average pain scores three times lower than the control
group by day 8 [104]. Although the aetiology of sore throat
in these patients is not always well defined, several treat-
ments show promise for the management of persistent sore
throat.
Studies in defined non-infectious sore throat populations
are few. Nimesulide and flurbiprofen were both found to be
effective in a randomised study of 60 patients with non-
infectious acute inflammation of the upper respiratory tract
[105]. Experimentally, paracetamol in combination with
caffeine reduces the nasal tonic pain elicited by dry air
provocation, and caffeine enhances and prolongs the
analgesia compared with control [106], supporting a role
for analgesics in non-infectious sore throat. Patients with
sore throat secondary to functional dysphonia may respond
to treatment of the underlying cause with vocal hygiene,
voice training, avoidance of irritants and allergens, and
co-medications (e.g. proton pump inhibitors, anti-allergic
drugs).
The most frequently studied non-infectious population is
that of postoperative sore throat and owing to its high
incidence, a great many studies have been conducted in
this area. For example, postoperative sore throat can be
prevented with inhaled fluticasone propionate [107],
intravenous dexamethasone [108], and lidocaine [30].
Other remedies include ketamine gargle [109], topical
NSAIDs including benzydamine [110], perioperative amyl-
metacresol/dichlorobenzyl alcohol lozenges (Strepsils)
[111], liquorice [112], and an azulene derivate from chamo-
mile [113].
These studies in defined populations with non-infectious
sore throat add to the data obtained in studies of less well-
defined acute and chronic sore throat. Although there is
currently a lack of rigorous trials of treatments for non-
infectious sore throat, there are enough data to suggest
there may be several effective strategies. The lack of a
suitable preclinical model hampers efforts to identify
effective new treatments.
The mechanism of non-infectious sore throat
The treatment of non-infectious sore throat could be
improved if the mechanisms were fully understood. How-
ever, the underlying pathophysiology, and components
such as individual disposition and potential receptors and
their interaction with irritants, are not yet well character-
ised. To complicate matters, the underlying mechanism
may vary with aetiology. Inflammation is a logical conse-
quence of infection of the upper respiratory tract.
Inflammation has also been implicated in non-infectious
aetiologies, with inflammatory cells and mediators isolated
from the upper respiratory tract (for example [114, 115]).
Mechanical trauma and injury is almost certainly the
precipitating factor in postoperative sore throat [25], as
supported by the preventive efficacy of some lubricants
[116]. The inflammatory response has been replicated in a
swine model, with elevated interleukin (IL) 6 and poly-
morphonuclear leukocytes found in tracheal lavage fluid
[117]. However, the precise aetiology and location of
postoperative sore throat remains unknown [25]. Factors
such as tracheal-tube size [118] and cuff design [119] have
been implicated during intubation [26], and sore throat
following the use of a laryngeal mask airway appears to be
related to the technique of insertion [31] and intracuff
pressure [26]. The problem is more common in older age
groups, and is related to grade of difficulty of intubation,
duration of surgery, and patient’s position during surgery
[29], with all factors probably reflecting an increased risk
of trauma.
The mechanism underlying sore throat in people with
gastroesophageal reflux disorder is likely to be chemical,
that is, due to refluxed gastric content, although indirect
effects through vagal (sensory) mechanisms have also been
implicated [42].
In rhinitis, pharyngeal irritation has been attributed to
the lymphoid hypertrophy and prominence of adenoidal
and tonsillar tissue, which results from chronic allergic
inflammation of the upper airway [120], and kinins gen-
erated in nasal secretions have been implicated [121]. The
mediators released after nasal challenge with allergens or
cold dry air are remarkably similar, including histamine,
leukotrienes, prostaglandin D2, and TAME-esterase [122].
The mechanism of cold air-induced rhinitis is well-char-
acterised, being associated with nasal mast cell activation
and sensory nerve stimulation (irritation) that generates a
cholinergic reflex leading to rhinorrhoea [98]. It seems
likely that the same mechanism may be responsible for
cold-induced sore throat—a useful experimental model
(see below).
Snoring is problematic in terms of identifying the
mechanism because although sore throat may cause snor-
ing, snoring may also cause sore throat [22]. The
mechanism is likely to be mechanical and similar to that
seen with dry air; sore throat is also associated with mouth
breathing [7, 22], obviously due to drying out of the pha-
ryngeal mucosa caused by unfiltered, unwarmed, non-
humidified air passage. Snoring-induced vibrations have
also been implicated in sore throat [22]. Similarly, it may
be physical stress on the pharynx that causes sore throat
following shouting and voice loading. Along with such
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mechanical mechanisms, emotional stress and stress-
induced subjective factors may also play a role, perhaps in
combination with muscle spasm. Excessive tension of the
(para) laryngeal musculature (due to psychological and
emotional factors, vocal misuse, or compensation for
underlying problems such as infection) [123] may result in
pain that could promote the persistence of lesions in the
laryngeal and pharyngeal mucosa.
The drugs that frequently (2–40 %) cause sore throat or
dry cough as a recognised adverse effect include ACE
inhibitors, which increase pro-inflammatory mediators
such as kinins, substance P, and prostaglandins [124]. For
this unwanted drug effect genetic predisposition factors
were found on corresponding receptors [124]. Switching
from ACE inhibitors to angiotensine receptor blockers is
the most accepted alternative to prevent elevated cytokines.
The mechanism by which inhaled corticosteroids cause
sore throat is less certain [37, 39]. Histologically, an
inflammatory infiltrate has been reported in some patients
[37] and locally-deposited steroid is likely to be a factor
[125]. In contrast, oral steroids alleviate the pain of acute
sore throat [13], probably due to their anti-inflammatory
action (because of the risk of side effects they are not a
routine therapeutic option in the long term). Chemotherapy
and radiotherapy cause sore throat as a consequence of
oropharyngeal mucositis [126].
These physico-chemical causes of sore throat, while not
fully elucidated, at least have plausible putative mecha-
nisms. The situation for many environmental insults is
more complex. Throughout the literature, the term ‘irri-
tants’ is used, but documented evidence of their identities
or the mechanism by which they might irritate and inflame
mucous membranes is scarce. For example, is it a physical
interaction or do the irritants bind to receptors that trigger a
deleterious response that manifests symptomatically as
sore throat? Identification of such receptors would certainly
go a long way to establishing the mechanism and providing
a therapeutic target.
Tobacco smoke is an often cited irritant [14]. It irritates
the stratified squamous epithelium of the oropharyngeal
mucosa [127] causing damage and reduced mucociliary
clearance, and impairs the immune response [128]. Nico-
tine binds to the nicotinic acetylcholine receptor on sensory
neurons [129, 130], and this is one of the proposed
mechanisms for irritation and pain caused by cigarette
smoke. However, chronic pain and an acute analgesic
effect of nicotine attenuated by desensitisation and/or
upregulation of the receptor on chronic exposure have also
been suggested [131]. Smoking also alters the resident flora
[132] predisposing to infection. Conversely, abstaining
from smoking for even one week causes a significant
increase in reports of sore throat (P = 0.049) and other
cold symptoms [133]. This is perhaps due to reduced
salivary immunoglobulin A [134]. Furthermore, the reason
for this unexpected observation might be rebound sensiti-
sation of (nicotinic acetylcholine) receptors.
Ozone has an inflammatory effect on both the upper and
lower respiratory tract, characterised by polymorph infil-
tration and release of pro-inflammatory cytokines [135–
137], although the specifics relating to sore throat are less
certain. The underlying mechanism is proposed to include a
direct effect of ozone on respiratory tract cell membranes
and fluid, with lipid ozonation products activating specific
lipases, triggering the release of endogenous mediators of
inflammation [138, 139] such as prostaglandin E, IL8,
thromboxane B2 and calcitonin gene-related peptide.
A straightforward chemical mechanism may underlie
the irritant effect of some environmental pollutants. For
example, in the presence of metal catalysts and moist air,
SO2 forms sulphuric acid and ammonium sulphate [45].
Other pollutants probably include NO2, and boron oxide
and boron acid. Sore throat in response to chemical odours
[68] could be due to irritation by the odorants themselves
or co-pollutants, or a learned aversion [140] which is well-
established for odorants.
Particulate matter, which contains both organic and
inorganic constituents, is associated with airway inflamma-
tion, apoptosis, genotoxicity, and oxidative stress [141–143].
Cement dust induces atrophic and hypertrophic changes in
nasal and pharyngeal mucosa and chronic exfoliative bron-
chitis in animal models [144]. Much of the extensive
research in the particulates field has been conducted in vitro,
but humans exposed to fuel oil ash have evidence of
inflammation, with increased IL8 and polymorphs in nasal
lavage fluid [114]. Induced sputum studies of fire fighters
10 months after the World trade centre disaster found levels
of neutrophils and eosinophils increased in relation to the
intensity of dust exposure [115].
Neurogenic inflammation may be responsible for the
airway response to particulate matter and other environ-
mental irritants such as ozone or sulphur dioxide [145,
146]. The irritants are proposed to interact with transient
receptor potential (TRP) channels. These ion channels are
found on sensory nerve fibres as well as immune and non-
immune cells in the respiratory tract, and their activation
results in the release of neuropeptides, such as calcitonin
gene-related peptide and substance P, that trigger inflam-
mation [147]. TRP channels are normally involved in
detection of the thermal, mechanical, and chemical stimuli
that are essential for survival [148].
Activated and sensitised TRP channels, particularly
TRPV1 and TRPA1, have been implicated in chronic air-
ways diseases (chronic obstructive pulmonary disease and
asthma) and the respiratory response to environmental
irritants [148, 149]. TRPV1 is activated by the potent
respiratory irritant capsaicin, but also by extracellular
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protons (generated during tissue acidosis and ischaemia)
and heat [149], and is also directly sensitised by nicotine
[148]. TRPA1 is activated by chlorine, reactive oxygen
species, and noxious constituents of smoke and smog
[149], as well as ginger and bradykinin [150]. It appears
that reactive respiratory irritants may activate TRPA1 by
covalent modification, with glutathione depletion perhaps
prolonging the effect [149]. The cumulative effect may
result in a reduced threshold for TRPA1 activation, such
that even low levels of smog or indoor pollutants elicit a
response [149].
Along with this direct activation of TRP channels by
irritants, the pain associated with inflammation may also be
mediated by TRP channels. TRPV1 and TRPA1 are both
activated and sensitised through inflammatory receptor
pathways [149]. Hence, when pro-inflammatory mediators
(such as histamine, prostaglandins, cysteinyl leucotrienes,
proteases, nerve growth factor, and bradykinin) bind to
their respective receptors on sensory neurons, this indi-
rectly results in TRP activation [149] via the endogenous
activating lipids produced by the phospholipase C and
phospholipase A2 pathways [148].
The field of TRP channel research is rapidly expanding, as
it becomes clear that these ion channels may be involved in a
vast range of diseases and chronic pain situations. Because
pain can be the result of overly sensitised TRP channels, it
follows that TRP desensitisation using agonists might pro-
vide relief [151]. This is supported by animal models, where
capsaicin desensitises the acute and inflammatory airway
response to a variety of noxious stimuli [149].
With the sensory role of TRPs in detecting a wide range
of thermal, mechanical, and chemical stimuli, TRP channel
activation and sensitisation—and the consequent triggering
of inflammation—potentially accounts for many of the
aetiologies of non-infectious sore throat, providing the
possibility of interactions of TRP channels and targets for
intervention. Along with TRPV1 and TRPA1, other pos-
sible mechanisms and targets for intervention include: the
somatosensory TRP channels, TRPM8, TRPV2 and
TRPV4 [152]; acid-sensing ion channel in the airway,
which detects acidity and toxic gasses [146]; and the
neuronal nicotinic acetylcholine-receptor [129, 130].
Experimental models of non-infectious sore throat
In order to fully elucidate the pathophysiology of non-
infectious sore throat, as well as assess the efficacy of any
potential treatments, models with defined conditions and
objective endpoints are required.
Many of the currently available models are not specific
for sore throat, and use subjective endpoints. Since the
sensation of pain is so subjective, asking patients to rate its
severity can often be the most appropriate endpoint.
Models for the study of non-allergic rhinitis and cough, but
not specifically sore throat, include challenge with metha-
choline, histamine, capsaicin [153], mechanical pressure
[154], and citric acid [155, 156]. In contrast, nasal provo-
cation with bradykinin induces sore throat as well as
rhinitis [121]. The sore throat pain model [157, 158], by
definition, provides specificity. However, it requires
patients to rate their throat pain on a visual analogue rating
scale and, as such, the endpoint is subjective.
There are some more specific animal models with
objective endpoints. Pharyngeal inflammation was induced
in a rat model by applying capsaicin directly to the pharyn-
geal mucosa [159]. Intubation has been used to induce
pharyngeal inflammation in a swine model [117] and lar-
yngeal inflammation in a rat model [160], with analysis of
biomarkers. Well-defined human models of pharyngeal
irritation with objective endpoints are generally lacking. One
that is in research use is the Tonsilliopharyngeal assessment
(TPA) scale which is based on a clinical examination of the
throat [158], although this still depends on the clinician’s
judgement. Currently, any correlation between subjective
and objective endpoints is therefore untested.
In humans, biomarkers, such as immune cells and
inflammatory mediators, are often experimentally mea-
sured in epidemiological studies, providing an objective
marker of airway inflammation. However, unless obtained
from a biopsy (which is too invasive for routine use), these
are not necessarily specific to the pharyngeal mucosa. For
example, analysis of bronchiolar lavage fluid reflects
inflammation occurring in the lungs but is relatively inva-
sive to perform, so not in common use. Tracheal lavage and
induced sputum techniques also sample mostly the lower
respiratory tract. Nasal lavage, which samples the upper
respiratory tract, gets closer to the pharyngeal mucosa, but
is still relatively specific to the nasal epithelium. In con-
trast, pharyngeal lavage [161] is site specific.
In humans, nasal challenge with cold dry air has been
used to experimentally replicate cold air-induced rhinitis
[97, 98, 153] and can be combined with the objective
analysis of biomarkers of nasal inflammation.
A new model of pharyngeal inflammation in humans
The lack of suitable models for the study of non-infectious
sore throat has hampered progress in elucidating mecha-
nisms and identifying treatments. A new model has been
developed using cold dry air (CDA) to experimentally
induce controlled inflammation in the pharynx of healthy
volunteers. The inflammation is then quantified by mea-
suring inflammatory mediators in pharyngeal lavage fluid
[unpublished].
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The model is a promising tool for future research
because it induces reversible pharyngeal irritation, in
controlled conditions, and is amenable to a crossover study
design. It may provide a valuable research tool and an
objective way of measuring the therapeutic potential of
treatments. Furthermore, this procedure may also allow for
research in occupational and environmental medicine
where exposure limits for single potential irritants exist but
interactions are not yet well established. In this way, a
CDA stimulus may be combined with one or two potential
irritants in order to generate comparable results in cross-
over study designs.
Conclusions
Despite how common non-infectious sore throat is, little is
understood about how it is caused by such a wide variety of
physico-chemical and environmental factors. It is possible
that in many cases the cause of persistent non-infectious
sore throat involves a combination of physico-chemical and
environmental factors. Inflammatory processes (of various
mechanisms, including neurogenic inflammation) appear to
underlie sore throat of non-infectious aetiologies, and in
many cases this may be the source of the pain. Cytokine
receptors and TRP channels seem to be involved in the
transduction pathways. Inflammation also underlies infec-
tious sore throat, so many of the therapeutic options may be
also appropriate for non-infectious sore throat. Indeed,
although limited, the literature suggests that appropriate
treatment options for non-infectious sore throat may include
drug therapy. However, the lack of suitable human experi-
mental models hampers the identification of drug therapy
(for example topical TRP antagonists). A new model using
cold dry air and pharyngeal lavage may provide a useful
tool for the study of mechanisms—including receptor
interactions—and treatment of non-infectious sore throat.
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